BioSymetrics, Janssen, Sema4 use AI to predict COVID-19

By The Science Advisory Board staff writers

August 19, 2020 -- BioSymetrics, Sema4, and Janssen Pharmaceuticals will use artificial intelligence (AI) to predict the onset and severity of COVID-19 among different populations.

The companies will use BioSymetrics' Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease. The goal of the collaboration is to enable a vaccine and a course of treatment against SARS-CoV-2.

If you like this content, please share it with a colleague!

Related Reading

AI Therapeutics begins COVID-19 phase II trial
AI Therapeutics has announced the start of a phase II trial for a COVID-19 treatment.

Repurpose.AI, Scripps collaborate on COVID-19 drug discovery
Repurpose.AI will collaborate with Scripps Research to develop COVID-19 therapeutics with a focus on drug repurposing.

NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...

J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...

How AI is speeding development of COVID-19 therapies
As the world is facing a new challenge in trying to both adapt to and defend itself against the novel coronavirus, artificial intelligence (AI) is offering...